BRPI0409763A - compostos de arila como moduladores de ppars, método de modulação, método de inibição da formação de adipócitos em um mamìfero, método de tratamento de uma doença ou uma condição modulada por ppar e composição farmacêutica - Google Patents
compostos de arila como moduladores de ppars, método de modulação, método de inibição da formação de adipócitos em um mamìfero, método de tratamento de uma doença ou uma condição modulada por ppar e composição farmacêuticaInfo
- Publication number
- BRPI0409763A BRPI0409763A BRPI0409763-7A BRPI0409763A BRPI0409763A BR PI0409763 A BRPI0409763 A BR PI0409763A BR PI0409763 A BRPI0409763 A BR PI0409763A BR PI0409763 A BRPI0409763 A BR PI0409763A
- Authority
- BR
- Brazil
- Prior art keywords
- ppar
- treating
- mammal
- condition
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"COMPOSTOS DE ARILA COMO MODULADORES DE PPARS, MéTODO DE MODULAçãO, MéTODO DE INIBIçãO DA FORMAçãO DE ADIPóCITOS EM UM MAMìFERO, MéTODO DE TRATAMENTO DE UMA DOENçA OU UMA CONDIçãO MODULADA POR PPAR E COMPOSIçãO FARMACêUTICA". Trata-se de compostos como moduladores de receptores ativados por proliferadores de peroxisoma, composições farmacêuticas que compreendem os mesmos, e métodos de tratamento de doença que fazem uso dos mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46458103P | 2003-04-17 | 2003-04-17 | |
PCT/US2004/010970 WO2004093879A1 (en) | 2003-04-17 | 2004-04-07 | (3-{3-‘(2,4-bis-trifluormethyl-benzyl)-(5-ethyl-pyrimidin-2-yl)-amino!-propoxy}-phenyl)-acetic acid and related compounds as modulators of ppars and methods of treating metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0409763A true BRPI0409763A (pt) | 2006-05-09 |
Family
ID=33310919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0409763-7A BRPI0409763A (pt) | 2003-04-17 | 2004-04-07 | compostos de arila como moduladores de ppars, método de modulação, método de inibição da formação de adipócitos em um mamìfero, método de tratamento de uma doença ou uma condição modulada por ppar e composição farmacêutica |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050070532A1 (pt) |
EP (1) | EP1613326B1 (pt) |
JP (1) | JP2006523698A (pt) |
KR (1) | KR100762762B1 (pt) |
CN (1) | CN1791409A (pt) |
AT (1) | ATE339205T1 (pt) |
AU (1) | AU2004231554A1 (pt) |
BR (1) | BRPI0409763A (pt) |
CA (1) | CA2520908A1 (pt) |
DE (1) | DE602004002394T2 (pt) |
ES (1) | ES2273282T3 (pt) |
MX (1) | MXPA05010812A (pt) |
WO (1) | WO2004093879A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7517884B2 (en) * | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
US20070208026A1 (en) * | 2003-04-07 | 2007-09-06 | Liu Kevin | N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders |
CA2521175A1 (en) * | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
ATE486055T1 (de) | 2004-05-05 | 2010-11-15 | High Point Pharmaceuticals Llc | Neue verbindungen, ihre herstellung und verwendung |
ATE515494T1 (de) | 2004-05-05 | 2011-07-15 | High Point Pharmaceuticals Llc | Neue verbindungen, deren herstellung und verwendung |
AU2005307006B2 (en) * | 2004-10-29 | 2012-05-03 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
US20070190079A1 (en) * | 2004-10-29 | 2007-08-16 | Kalypsys, Inc. | Methods for the selective modulation of ppar |
US7301033B2 (en) | 2005-01-27 | 2007-11-27 | Kowa Co., Ltd. | PPAR-activating compound |
TW200640887A (en) * | 2005-01-27 | 2006-12-01 | Kowa Co | PPAR-activating compound |
AU2006265172B2 (en) | 2005-06-30 | 2011-09-15 | Vtv Therapeutics Llc | Phenoxy acetic acids as PPAR delta activators |
JP2009509988A (ja) | 2005-09-29 | 2009-03-12 | サノフィ−アベンティス | フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用 |
ES2691548T3 (es) * | 2005-10-25 | 2018-11-27 | Kalypsys, Inc. | Sales de moduladores de PPAR y métodos para tratar desórdenes metabólicos |
EP2386540A1 (en) | 2005-12-22 | 2011-11-16 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
US7943612B2 (en) | 2006-03-09 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds that modulate PPAR activity, their preparation and use |
WO2007109577A1 (en) * | 2006-03-17 | 2007-09-27 | Kalypsys, Inc. | Alkylamine-substituted bicyclic aryl compounds useful as modulators of ppar |
US20070249519A1 (en) * | 2006-04-20 | 2007-10-25 | Kalypsys, Inc. | Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease |
TW200745059A (en) * | 2006-05-16 | 2007-12-16 | Kalypsys Inc | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9600464D0 (en) * | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
AU2002224139A1 (en) * | 2000-12-05 | 2002-06-18 | Nippon Chemiphar Co. Ltd. | Ppar (peroxisome proliferator activated receptor) activators |
CN100577660C (zh) * | 2002-09-12 | 2010-01-06 | 霍夫曼-拉罗奇有限公司 | 作为ppar激动剂用于治疗糖尿病的n-取代-1h-吲哚-5-丙酸化合物 |
WO2004058174A2 (en) * | 2002-12-20 | 2004-07-15 | Bayer Pharmaceuticals Corporation | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
-
2004
- 2004-04-07 US US10/820,647 patent/US20050070532A1/en not_active Abandoned
- 2004-04-07 AU AU2004231554A patent/AU2004231554A1/en not_active Abandoned
- 2004-04-07 AT AT04759820T patent/ATE339205T1/de not_active IP Right Cessation
- 2004-04-07 WO PCT/US2004/010970 patent/WO2004093879A1/en active IP Right Grant
- 2004-04-07 KR KR1020057019603A patent/KR100762762B1/ko not_active IP Right Cessation
- 2004-04-07 JP JP2006509849A patent/JP2006523698A/ja active Pending
- 2004-04-07 BR BRPI0409763-7A patent/BRPI0409763A/pt not_active IP Right Cessation
- 2004-04-07 EP EP04759820A patent/EP1613326B1/en not_active Expired - Lifetime
- 2004-04-07 CN CNA2004800103500A patent/CN1791409A/zh active Pending
- 2004-04-07 CA CA002520908A patent/CA2520908A1/en not_active Abandoned
- 2004-04-07 MX MXPA05010812A patent/MXPA05010812A/es not_active Application Discontinuation
- 2004-04-07 ES ES04759820T patent/ES2273282T3/es not_active Expired - Lifetime
- 2004-04-07 DE DE602004002394T patent/DE602004002394T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20060082788A (ko) | 2006-07-19 |
ES2273282T3 (es) | 2007-05-01 |
JP2006523698A (ja) | 2006-10-19 |
MXPA05010812A (es) | 2006-03-30 |
CA2520908A1 (en) | 2004-11-04 |
CN1791409A (zh) | 2006-06-21 |
DE602004002394T2 (de) | 2007-09-13 |
DE602004002394D1 (de) | 2006-10-26 |
EP1613326A1 (en) | 2006-01-11 |
EP1613326B1 (en) | 2006-09-13 |
US20050070532A1 (en) | 2005-03-31 |
KR100762762B1 (ko) | 2007-10-17 |
WO2004093879A1 (en) | 2004-11-04 |
ATE339205T1 (de) | 2006-10-15 |
AU2004231554A1 (en) | 2004-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0409763A (pt) | compostos de arila como moduladores de ppars, método de modulação, método de inibição da formação de adipócitos em um mamìfero, método de tratamento de uma doença ou uma condição modulada por ppar e composição farmacêutica | |
TW200607491A (en) | Aryl sulfonamide and sulfonyl compounds as modulators of ppar and methods of treating metabolic disorders | |
MX2007005205A (es) | Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma. | |
BRPI0518222A (pt) | composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos | |
TW200602330A (en) | Compounds and compositions as PPAR modulators | |
ATE472529T1 (de) | Prolinamidderivate als natriumkanalmodulatoren | |
EA201190138A1 (ru) | Производные фуропиримидиндиона в качестве модуляторов trpa1 | |
MX2007004765A (es) | Compuestos y metodos que modulan la actividad de la trombopoyetina. | |
DE602005017895D1 (de) | Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren | |
ATE322258T1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
UA111579C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
CL2008003825A1 (es) | Compuestos derivados de 4-pirrolidinbenzonitrilo, moduladores selectivos de receptores de androgeno; composicion farmaceutica; kit farmaceutico; y su uso en el tratamiento de una enfermedad o trastorno seleccionada de piel envejecida, enfermedad de alzheimer, anemia, artritis, gota, arterosclerosis, enfermedad osea, entre otras. | |
DE602007013991D1 (de) | Haarsträhnungsapplikator und Verfahren | |
NO20092444L (no) | Heteroarylamidderivater | |
ATE515268T1 (de) | Verwendung von op-1 zur behandlung von knorpeldefekten | |
NO20054396D0 (no) | 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
BRPI0408220A (pt) | composto, isÈmeros, composição farmacêutica, e, métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa em um mamìfero e de tratar, prevenir ou controlar uma doença ou condição | |
BR0309278A (pt) | Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto | |
MA55147A (fr) | Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte | |
MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
DE60333211D1 (de) | Neue verbindungen und deren verwendung als ppar-modulatoren | |
BR0315247A (pt) | Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |